Whiting James F, Kiberd Bryce, Kalo Zoltan, Keown Paul, Roels Leo, Kjerulf Maria
Maine Medical Center, Portland, ME, USA.
Am J Transplant. 2004 Apr;4(4):569-73. doi: 10.1111/j.1600-6143.2004.00373.x.
Initiatives aimed at increasing organ donation can be considered health care interventions, and will compete with other health care interventions for limited resources. We have developed a model capable of calculating the cost-utility of organ donor initiatives and applied it to Donor Action, a successful international program designed to optimize donor practices. The perspective of the payer in the Canadian health care system was chosen. A Markov model was developed to estimate the net present value incremental lifetime direct medical costs and quality adjusted life years (QALYs) as a consequence of increased kidney transplantation rates. Cost-saving and cost-effectiveness thresholds were calculated. The effects of changing the success rate and time frame of the intervention was examined as a sensitivity analysis. Transplantation results in a gain of 1.99 QALYs and a cost savings of Can$104,000 over the 20-year time frame compared with waiting on dialysis. Implementation of an intervention such as Donor Action, which produced as few as three extra donors per million population, would be cost-effective at a cost of Can$1.0 million per million population. The cost-effectiveness of Donor Action and other organ donor initiatives compare favorably to other health care interventions. Organ donation may be underfunded in North America.
旨在增加器官捐赠的举措可被视为医疗保健干预措施,并且会与其他医疗保健干预措施竞争有限的资源。我们开发了一个能够计算器官捐赠者举措成本效益的模型,并将其应用于“捐赠者行动”,这是一个旨在优化捐赠实践的成功国际项目。我们选择了加拿大医疗保健系统中付款人的视角。开发了一个马尔可夫模型,以估计由于肾移植率提高而导致的净现值增量终身直接医疗成本和质量调整生命年(QALY)。计算了成本节约和成本效益阈值。作为敏感性分析,研究了改变干预成功率和时间框架的影响。与等待透析相比,在20年的时间框架内,移植可带来1.99个QALY的收益,并节省104,000加元的成本。实施诸如 “捐赠者行动” 这样的干预措施,即每百万人口中只需增加三名捐赠者,每百万人口成本为100万加元时,将具有成本效益。“捐赠者行动” 和其他器官捐赠举措的成本效益与其他医疗保健干预措施相比更具优势。在北美,器官捐赠的资金可能不足。